Adjuvant Therapy of Skin Melanoma With Alpha Interferon and Naderin

The goal of this clinical trial is to learn if adding alpha interferon to standard treatment works to prevent skin melanoma from coming back after surgery. The study will also learn if different doses of alpha interferon work better than others. The main questions it aims to answer are: * Does alpha interferon help people with melanoma live longer without the cancer returning? * Does a higher dose of alpha interferon work better than a lower dose? * How does alpha interferon affect the immune system? Researchers will compare six different treatment approaches to see which one works best. Participants will: * Have surgery to remove their melanoma * Receive one of six different treatments after surgery: * Radiation therapy (40 Gy) * Low-dose interferon (3 million IU) * Surgery alone (no additional treatment) * High-dose interferon (9 million IU/m² IV) * Low-dose interferon with chemotherapy (dacarbazine + cisplatin) * Chemotherapy alone (dacarbazine + cisplatin) * Have regular check-ups to see if the cancer returns * Have blood tests to check immune system function Key finding: The study will determine which treatment approach provides the best chance of survival without cancer recurrence.

NCT Number	NCT07671495
Lead Sponsor	MIPO Clinic Collaborators: Asfendiyarov Kazakh National Medical University, Kazakh Research Institute of Oncology & Radiology
Conditions	Melanoma Stage I, Melanoma Stage III, Melanoma Stage II, Skin Melanoma
Enrollment	278 participants
Start Date	2014-01
Primary Completion	2017-12 (estimated)
Study Completion	2018-12 (estimated)
Updated on ClinicalTrials.gov	2026-06-30